Home > Boards > US OTC > Medical - Healthcare > BioLight Life Sciences Ltd. ADR (BLGTY)

Zacks Reiterates “Outperform” Rating for BIO-LIGHT ISRAELI (BLGTY)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 127
Posts 25,940
Boards Moderated 7
Alias Born 02/07/04
160x600 placeholder
midastouch017   Sunday, 10/05/14 09:55:08 AM
Re: None
Post # of 48 
Zacks Reiterates “Outperform” Rating for BIO-LIGHT ISRAELI (BLGTY)
September 30th, 2014

BIO-LIGHT ISRAELI logoZacks restated their outperform rating on shares of BIO-LIGHT ISRAELI (NASDAQ:BLGTY) in a report released on Tuesday. Zacks currently has a $14.00 price objective on the stock.

Zacks’ analyst wrote, “BioLight Israeli Life Sciences invests in, manages and commercializes biomedical innovations in the field of ophthalmology and cancer diagnostics. The company offers a rich portfolio of products, of which, IOPtiMate , laser surgical device for glaucoma and CellDetect cell staining technology for detecting and monitoring cancer cells, had a soft launch at the beginning of this year BioLight’s products address a large untapped market which provides an attractive investment opportunity. We initiate coverage on BioLight with an outperform rating.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences